GelStat Corporation (GSAC) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören GelStat Corporation (GSAC), 0 değerindeki bir Healthcare şirketidir. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 65/100 puan alıyor.
Son analiz: 17 Mar 2026GelStat Corporation (GSAC) Sağlık ve Boru Hattı Genel Bakışı
GelStat Corporation operates in the consumer healthcare sector, developing and marketing over-the-counter products like GelStat Migraine and Chews 2 Lose. With a small team and focus on non-prescription solutions, the company faces competition from larger generic drug manufacturers and established consumer health brands in a fragmented market.
Yatırım Tezi
GelStat Corporation presents a high-risk, high-reward investment profile. The company's small market capitalization and limited resources make it vulnerable to market fluctuations and competitive pressures. A potential upside lies in the successful commercialization of its existing product line and the development of new OTC products. With a negative P/E ratio of -3.37 and a negative profit margin of -73.3%, the company's financial performance needs significant improvement. The company's beta of 1.26 indicates higher volatility compared to the market. Investors should carefully consider the risks associated with investing in a small, OTC-listed company with limited financial resources and a concentrated product portfolio.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market Cap of $0.00B reflects the company's small size and limited market presence.
- P/E Ratio of -3.37 indicates the company is currently not profitable.
- Profit Margin of -73.3% highlights significant challenges in achieving profitability.
- Gross Margin of 70.3% suggests potential for profitability if operating expenses are managed effectively.
- Beta of 1.26 indicates higher volatility compared to the overall market.
Rakipler & Benzerleri
Güçlü Yönler
- Patented GelStat Migraine formula.
- Established distribution network.
- Focus on over-the-counter products.
- Gross margin of 70.3% indicates potential profitability.
Zayıflıklar
- Small market capitalization.
- Limited financial resources.
- Negative profit margin.
- High dependence on a few key products.
Katalizörler
- Upcoming: Potential FDA approval for new OTC products in development.
- Ongoing: Expansion of distribution network to new retailers and wholesalers.
- Ongoing: Increased marketing efforts to drive product awareness and sales.
Riskler
- Potential: Intense competition from larger pharmaceutical companies.
- Potential: Stringent regulatory requirements and potential product recalls.
- Ongoing: Limited financial resources and potential need for additional funding.
- Ongoing: Dependence on a few key products and potential for declining sales.
- Potential: Product liability claims and associated legal expenses.
Büyüme Fırsatları
- Expansion of Product Line: GelStat can expand its product line by developing new OTC products targeting specific health concerns. The market for OTC products is vast, with opportunities in areas such as pain management, digestive health, and immune support. Successful development and launch of new products could drive revenue growth and increase market share. The timeline for this growth opportunity depends on the company's ability to secure funding for R&D and navigate regulatory approval processes.
- Strategic Partnerships: GelStat can pursue strategic partnerships with larger pharmaceutical companies or distributors to expand its market reach and access new distribution channels. Collaborations could provide access to established sales networks and marketing resources, accelerating product adoption and revenue growth. The timeline for this growth opportunity depends on the company's ability to identify and secure suitable partners.
- E-commerce Expansion: GelStat can invest in expanding its e-commerce presence to reach a wider customer base and capitalize on the growing trend of online shopping. Developing a user-friendly online platform and implementing effective digital marketing strategies could drive online sales and increase brand awareness. The timeline for this growth opportunity depends on the company's ability to invest in technology and digital marketing resources.
- Geographic Expansion: GelStat can explore opportunities to expand its geographic reach by entering new markets outside of the United States. International expansion could provide access to new customer segments and diversify revenue streams. The timeline for this growth opportunity depends on the company's ability to navigate international regulatory requirements and establish distribution networks in new markets.
- Focus on Niche Markets: GelStat can focus on developing and marketing products for niche markets with specific health needs. By targeting underserved segments of the population, the company can differentiate itself from larger competitors and build a loyal customer base. The timeline for this growth opportunity depends on the company's ability to identify and understand the needs of specific niche markets.
Fırsatlar
- Expansion of product line.
- Strategic partnerships with larger companies.
- E-commerce expansion.
- Geographic expansion into new markets.
Tehditler
- Intense competition from larger companies.
- Stringent regulatory requirements.
- Changing consumer preferences.
- Potential product liability claims.
Rekabet Avantajları
- Patented GelStat Migraine formula provides some protection.
- Established relationships with retailers and distributors.
- Brand recognition among consumers seeking specific OTC solutions.
GSAC Hakkında
GelStat Corporation, headquartered in Palm City, Florida, is a consumer healthcare company engaged in the research, development, and marketing of over-the-counter (OTC) and other non-prescription consumer healthcare products. The company's portfolio includes GelStat Migraine, a patented product designed to provide pain relief from migraine headaches. Other products include Chews 2 Lose, an appetite suppressant gum intended as a diet aid; All Natural Speed, an energy supplement; and GelStat Sleep, a product formulated to alleviate sleep disorders and associated symptoms. GelStat Corporation distributes its products through a network of retailers, wholesalers, specialty distributors, and catalog merchandisers, utilizing both direct sales and external sales brokers. Founded with the aim of providing accessible consumer health solutions, GelStat Corporation has focused on developing and commercializing products that address common health concerns. The company's strategy involves identifying market needs and formulating products that can be sold directly to consumers without requiring a prescription. Despite its efforts, the company faces challenges in a competitive market dominated by larger players with greater resources and established brand recognition.
Ne Yaparlar
- Researches and develops over-the-counter (OTC) healthcare products.
- Markets and sells non-prescription consumer health products.
- Offers GelStat Migraine for migraine pain relief.
- Provides Chews 2 Lose appetite suppressant gum.
- Sells All Natural Speed energy supplements.
- Offers GelStat Sleep for relief from sleep disorders.
- Distributes products through retailers, wholesalers, and distributors.
İş Modeli
- Develops and patents over-the-counter healthcare products.
- Manufactures or outsources the production of its products.
- Sells products directly to retailers, wholesalers, and distributors.
- Generates revenue through product sales.
Sektör Bağlamı
GelStat Corporation operates within the competitive and highly regulated drug manufacturers - specialty & generic industry. This sector is characterized by intense competition, stringent regulatory requirements, and evolving consumer preferences. The market for over-the-counter (OTC) drugs and non-prescription healthcare products is substantial, driven by increasing consumer awareness and a desire for self-care solutions. However, companies like GelStat face challenges from larger, more established players with greater resources and broader distribution networks. The industry is also subject to regulatory scrutiny from agencies like the FDA, which impacts product development, manufacturing, and marketing activities.
Kilit Müşteriler
- Retailers selling OTC healthcare products.
- Wholesalers distributing healthcare products.
- Specialty distributors focusing on specific product categories.
- Consumers seeking non-prescription health solutions.
Finansallar
Grafik & Bilgi
GelStat Corporation (GSAC) hisse senedi fiyatı: Price data unavailable
Son Haberler
GSAC için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
GSAC için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
GSAC için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, GSAC'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Javier G. Acosta
CEO
Javier G. Acosta serves as the CEO of GelStat Corporation. Information regarding his detailed career history and educational background is not available in the provided data. As the managing executive of a small team of two employees, Acosta's role likely involves overseeing all aspects of the company's operations, from product development and marketing to sales and distribution. His leadership is critical to the company's ability to navigate the competitive consumer healthcare market and achieve its strategic goals.
Sicil: Due to the limited information available, it is difficult to assess Javier G. Acosta's specific track record at GelStat Corporation. However, as CEO, he is responsible for guiding the company's strategic direction and overseeing its day-to-day operations. Key milestones under his leadership would include product launches, distribution agreements, and any improvements in the company's financial performance. The success of GelStat Migraine and other OTC products would be indicators of his leadership effectiveness.
GSAC OTC Piyasa Bilgileri
The OTC Other tier, also known as the Pink Market, represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no reporting requirements, meaning they may not be required to file financial statements with the SEC. This lack of transparency increases the risk for investors, as there is less information available to assess the company's financial health and operations. Companies in this tier are often speculative and may be subject to significant price volatility.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited or no financial reporting requirements.
- Lack of regulatory oversight.
- High potential for fraud and manipulation.
- Significant price volatility.
- Illiquidity and difficulty in buying or selling shares.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Determine if the company is subject to SEC reporting requirements.
- Company has been in operation for several years.
- Company has a patented product (GelStat Migraine).
- Company has established relationships with retailers and distributors.
- Company has a functional website and contact information.
- Company's products are available for sale through various channels.
GSAC Healthcare Hisse Senedi SSS
GSAC için değerlendirilmesi gereken temel faktörler nelerdir?
GelStat Corporation (GSAC) şu anda yapay zeka skoru 65/100, orta puanı gösteriyor. Temel güçlü yan: Patented GelStat Migraine formula.. İzlenmesi gereken birincil risk: Potential: Intense competition from larger pharmaceutical companies.. Bu bir finansal tavsiye değildir.
GSAC MoonshotScore'u nedir?
GSAC şu anda MoonshotScore'da 65/100 (Derece B) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
GSAC verileri ne sıklıkla güncellenir?
GSAC fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler GSAC hakkında ne diyor?
GSAC için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
GSAC'a yatırım yapmanın riskleri nelerdir?
GSAC için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Intense competition from larger pharmaceutical companies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
GSAC'ın P/E oranı nedir?
GSAC için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için GSAC'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
GSAC aşırı değerli mi, yoksa düşük değerli mi?
GelStat Corporation (GSAC)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
GSAC'ın temettü verimi nedir?
GelStat Corporation (GSAC) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited information available on the company's financial performance and operations.
- OTC listing increases the risk of investing in GSAC.
- Analyst coverage is not available for GSAC.